1.56
-0.03(-1.89%)
Currency In USD
| Previous Close | 1.59 |
| Open | 1.57 |
| Day High | 1.67 |
| Day Low | 1.54 |
| 52-Week High | 5.17 |
| 52-Week Low | 0.95 |
| Volume | 1.07M |
| Average Volume | 871,618 |
| Market Cap | 168.35M |
| PE | -0.91 |
| EPS | -1.71 |
| Moving Average 50 Days | 2.28 |
| Moving Average 200 Days | 1.87 |
| Change | -0.03 |
If you invested $1000 in Aclaris Therapeutics, Inc. (ACRS) since IPO date, it would be worth $141.82 as of March 14, 2025 at a share price of $1.56. Whereas If you bought $1000 worth of Aclaris Therapeutics, Inc. (ACRS) shares 5 years ago, it would be worth $1,782.86 as of March 14, 2025 at a share price of $1.56.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
GlobeNewswire Inc.
Mar 04, 2025 12:00 PM GMT
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company w
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
GlobeNewswire Inc.
Feb 12, 2025 11:50 AM GMT
- Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company foc
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
GlobeNewswire Inc.
Jan 30, 2025 9:01 PM GMT
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a